1. Medtech Insight
  2. >>Device Area

RedDress Chronic Wound Treatment Wins Medicare Coverage

 
• By Elizabeth Orr

The ActiGraft PRO treatment for diabetic ulcers recently procured Medicare coverage nationwide, despite anti-abuse policies that have made reimbursement for new wound care products rare. Company general manager Robert Mueller talked about the process.

ActiGraft pro packaging, as well as demonstrations of the product in use.
• Source: RedDress Ltd.

Reimbursement for wound care products has been in flux in recent years, with Medicare and its contractors restricting the range of products covered for beneficiaries as the agency grappled with ongoing problems caused by fraud and ineffective treatments.

But recent CMS decisions will allow greater access to novel whole-blood treatments, Robert Mueller, general manager of Israeli wound care firm RedDress, Ltd.., told Medtech Insight.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Wound Management

Amferia Aims To Bring Peptide Hydrogel To Fight Against Antimicrobial Resistance

 
• By Natasha Barrow

Amferia is developing an antimicrobial peptide hydrogel dressing to combat infections in acute wounds in humans and veterinary contexts. Supported by €1.2m of new venture capital financing, the company is planning pivotal clinical studies to support an FDA application later this year and CE mark submission in 2026-2027.

Cresilon’s FDA-Cleared Traumagel Stops Severe Bleeding Instantly, Available In US In Late 2024

 
• By Marion Webb

Cresilon CEO Joe Landolina says the newly FDA-cleared Traumagel for moderate and severe bleeding is easier to use than many currently available solutions like gauzes and sponges, and provides faster results.

Podcast: AMR, UTI, Breathomics And 3D Printing Technology Innovators Profiled At BioWales 2024

 
• By Ashley Yeo

Breathomics, UTI diagnosis and advanced wound healing innovations were among the center stage technologies at BioWales in London 2024. Hear from CEO John McKinley on Imspex Diagnostics' plans in embedded podcast.  

Podcast: AMR, UTI, Breathomics And 3D Printing Technology Innovators Profiled At BioWales 2024

 
• By Ashley Yeo

Breathomics, UTI diagnosis and advanced wound healing innovations were among the center stage technologies at BioWales in London 2024.

More from Device Area

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 
• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

Zika Virus Test Among 4 New FDA Device Classifications

 
• By Elizabeth Orr

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

Salvia Bioelectronics Secures $60M In Series B To Advance Chronic Migraine Implant, Eyes US Trials

 
• By Marion Webb

Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.